The Latest: India drugmaker to produce Sputnik V doses
Russia’s sovereign wealth fund announced a manufacturing deal with the Indian pharmaceutical maker Virchow Biotech Private Limited for making 200 million doses of the Sputnik V vaccine each year
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.NEW DELHI, India — Russia’s sovereign wealth fund announced a manufacturing deal with the Indian pharmaceutical maker Virchow Biotech Private Limited for making 200 million doses of the Sputnik V vaccine each year.
This is the fourth manufacturing deal announced by Russia and 700 million doses of the Russian vaccine will now be made in India.
Last week, two manufacturing deals for the vaccine in India were announced: Gland Pharma Pvt Ltd., a subsidiary of Chinese pharmaceutical company Fosun Pharma, said Tuesday it would 252 million doses vaccine and Stelis Biopharma partnered to produce and supply 200 million doses of the vaccine. Earlier, a deal to make 100 million doses of the vaccine annually was announced by Indian pharmaceutical firm Hetero Biopharma.
India has been pledged 125 million doses of the vaccine by Russia.
___
THE VIRUS OUTBREAK:
— AstraZeneca: US data shows vaccine effective for all ages
— Germany looks set to extend lockdown measures again
— Taiwan gives health workers island’s first AstraZeneca doses
— Teachers lament ‘chaotic’ virus rules in German schools
___
Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic, https://apnews.com/hub/coronavirus-vaccine and https://apnews.com/UnderstandingtheOutbreak
___
HERE’S WHAT ELSE IS HAPPENING:
LONDON — AstraZeneca’s COVID-19 vaccine provided strong protection against sickness and eliminated hospitalizations and deaths from the disease across all age groups in a late-stage study in the United States, the company announced Monday.
AstraZeneca said its experts did not identify any safety concerns related to the vaccine, including finding no increased risk of rare blood clots identified in Europe.
Although AstraZeneca’s vaccine has been authorized in more than 50 countries, it has not yet been given the green light in the U.S. — and has struggled to gain public trust amid a troubled rollout. The study comprised more than 30,000 volunteers, of whom two-thirds were given the vaccine while the rest got dummy shots.
___
BERLIN — Cross-border commuters have lined up at a newly opened testing station on the Polish-German border after Germany reacted to rising coronavirus infections in Poland by imposing new restrictions.
Germany declared Poland a “high-incidence area” starting Sunday, meaning that most people now need a negative test taken with the last 48 hours to enter and need to go into quarantine. Regular work commuters have to get tested twice a week.
Germany didn't set up full border checks of the kind that have been place on its border with the two countries’ worse-hit neighbor, the Czech Republic, for weeks.
But the dpa news agency reported that there was a long line early Monday morning for a new testing station set up in Frankfurt an der Oder — one of three in Germany’s Brandenburg state. About 150 people waited in frosty temperatures to get tested.
___
VILNIUS, Lithuania — The president, prime minister and speaker of the parliament of the Baltic country all rolled up their sleeves Monday in a public move to boost general public’s trust in the AstraZeneca jab.
Last week, the Lithuanian health ministry halted the vaccine but authorized again nationwide two days later.
“I encourage our people not to linger any longer and get the jab with the vaccine of their preference” President Gitranas Nauseda told reporters Monday morning. He and Ingrida Simonyte and Viktorija Cmilyte Nielsen — respectively the prime minister and the speaker of the 141-member Seimas assembly — received the vaccine.
Lithuania has reported more than 209,000 cases and 3,476 deaths from COVID-19 since the start of pandemic in 2020. A massive vaccination campaign is planned to start later this spring.
___
ATHENS, Greece — Greece’s health minister is requisitioning the services of private sector doctors from certain specialties in the wider Athens region to help fight a renewed surge in coronavirus infections that is straining hospitals to their limits.
Vassilis Kikilias said Monday that despite repeated appeals to private sector doctors to volunteer to help in the public sector, very few came forward. Therefore, he said, he was ordering those from the specialties of pathology, pneumonology and general medicine to help.
The requisition order is for one month for 206 doctors, health authorities said.
___
TAIPEI, Taiwan — Health care workers received the first shots in Taiwan’s COVID-19 vaccination drive Monday, beginning a campaign that won’t use supplies from China amid uneven distribution of the vaccines globally.
Taiwan has on hand 117,000 doses of the AstraZeneca vaccine, which it is distributing to healthcare workers across 57 hospitals.
Taiwanese premier Su Tseng-chang launched the drive by receiving the first shot at National Taiwan University Hospital in the capital Taipei. “After 30 minutes of rest, there’s no signs of any discomfort,” he said.
The rest period is for monitoring recipients for any adverse reactions.